Canadian Treat and Extend Analysis Trial With Ranibizumab

Exclusion Criteria

• •Patients with structural foveal damage in the study eye,
• •Patients with confounding severe oculare diseases,
• •Patients with suspicion of ( Polypoidal Choroidal Vasculapathy PCV) in the study eye,
• •Patients with active or suspected or periocular infections in either eye or active intraocular inflammation in either eye,
• •Patients who had previous subfoveal laser photocoagulation in the study eye or history of vitrectomy surgery in the study eye,
• •Patients who had any prior treatment in the study eye, e.g., with Visudyne\*, Avastin\*, prior Ranibizumab treatment, Ozurdex\*, external radiation therapy, transpupillary thermotherapy (TTT), or any intravitreal injection,
• •Patients with a known sensitivity to Ranibizumab or any component of its formulation,
• •Patients who have used any investigational agent in the last 30 days,
• •Concurrent participation in a clinical trial or within 30 days prior to enrollment,
• •Patients having received systemic treatment with any other anti-vascular endothelial growth factor (VEGF) therapy ≤ 60 days prior to enrollment
• •Patients with physical or mental disabilities that prevent accurate vision testing,
• •Patients physically unable to tolerate intravenous fluorescein angiography,
• •Pregnant or breastfeeding female patients,
• •Any patient with recent history of new onset cardiac disease or thromboembolic central nervous system (CNS) event (within 12 months of Baseline Visit),
• •Patients with any other condition which, in the opinion of the Investigator, would require treatment that would significantly impact the treatment assessments during this study.